For the first time, children in the United States will have a non-drug option for treating attention deficit hyperactivity disorder (ADHD). The FDA just cleared the Monarch external Trigeminal Nerve Stimulation (eTNS) System from NeuroSigma, a Los Angeles, California company, to treat ADHD in kids between 7 and 12 years old. The system has already (Read more...)